富马酸沃诺拉赞 T21254

Product Introduction
Bioactivity


英文名: Vonoprazan Fumarate

描述: Vonoprazan Fumarate (TAK438) 是质子泵的有效抑制剂，是口服有效的高效钾竞争性酸阻断剂，具有抗分泌活性。在 pH 为 6.5 时，它抑制猪胃微粒体中的 H+,K+-ATPase 酶活性，IC50为 19 nM。它被开发用于研究酸相关疾病，如消化性溃疡和胃食管反流病。

体外活性: The inhibitory activity of Vonoprazan Fumurate was unaffected by ambient pH. The inhibition by Vonoprazan Fumurate was reversible and achieved in a K(+)-competitive manner, quite different from that by lansoprazole. Vonoprazan Fumurate exhibits porcine gastric H+ ,K+-ATPase activity in a concentration-dependent manner[4].

体内活性: Vonoprazan Fumurate, at a dose of 4 mg/kg (as the free base) orally, completely inhibited basal and 2-deoxy-d-glucose-stimulated gastric acid secretion in rats, and its effect on both was stronger than that of lansoprazole. Vonoprazan Fumurate increased the pH of gastric perfusate to a higher value than did lansoprazole or SCH28080, and the effect of Vonoprazan Fumurate was sustained longer than that of lansoprazole or SCH28080[4].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 4.61 mg/mL (10 mM)


关键字: peptic | potassium | secretion | reflux | competitive | proton | inhibitor | antisecretory | disease | gastroesophageal | inhibit | Vonoprazan | ulcer | GERD | blocker | acid | gastric | Vonoprazan Fumarate | pump | P-CAB | Proton Pump

相关产品: Tenatoprazole | Ilaprazole sodium hydrate | Pumaprazole | Esomeprazole Sodium | Lansoprazole-d4 | (R)-Lansoprazole | Lansoprazole Sulfide D4 | Pantoprazole sodium | Bamaquimast | Rabeprazole Sulfide

相关库: FDA-Approved Drug Library | Drug Repurposing Compound Library | FDA-Approved & Pharmacopeia Drug Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Anti-Cancer Approved Drug Library | Exosome Compound Library | Bioactive Compound Library

富马酸沃诺拉赞 T21254信息由TargetMol中国为您提供，如您想了解更多关于富马酸沃诺拉赞 T21254报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途